drugset / Trial / NCT03441204

REgistry-based Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX)

NCT03441204

RandomizedParallel-groupOpen-labelTreatment

Summary

Multicenter, phase IV, non-superiority, registry-based, randomized controlled trial. Patients starting long-term oxygen therapy (LTOT) are randomized between LTOT prescribed 24 h/day or 15 h/day using the Swedish Register for Respiratory Failure (Swedevox). Clinical follow-up and concurrent treatments are according to routine clinical practice. The main endpoints of mortality, hospitalizations, and incident disease are assessed using Swedish registry data, with expected complete follow-up. Patient-reported outcomes are assessed using a posted questionnaire at 3 and 12 months. The study is managed by the Uppsala Clinical Research Centre (UCR).

Timeline

Start
2018-05-16
Primary completion
2022-04-04
Completion
2023-04-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxygen Other / unclassified Intranasal

Indications